Annette Langer-Gould to Retrospective Studies
This is a "connection" page, showing publications Annette Langer-Gould has written about Retrospective Studies.
Connection Strength
1.936
-
Anti-NMDA receptor encephalitis outcomes in a population-based cohort. J Neurol. 2026 Jul 15; 273(8).
Score: 0.147
-
De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy. Mult Scler. 2026 Apr; 32(4):409-420.
Score: 0.143
-
Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 2026 Jan 27; 106(2):e214473.
Score: 0.141
-
Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2024 Jul; 11(4):e200255.
Score: 0.126
-
Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections. Neurol Neuroimmunol Neuroinflamm. 2024 May; 11(3):e200211.
Score: 0.125
-
Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023 Nov; 10(6).
Score: 0.121
-
Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. JAMA Netw Open. 2022 12 01; 5(12):e2248664.
Score: 0.114
-
Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness. Int J Infect Dis. 2023 Jan; 126:87-93.
Score: 0.114
-
High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectiveness. Int J Infect Dis. 2022 Dec; 125:184-191.
Score: 0.113
-
Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022 05 03; 98(18):e1818-e1827.
Score: 0.110
-
Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021 04; 8(4):938-943.
Score: 0.102
-
Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2021 03; 8(2).
Score: 0.101
-
Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infect Dis. 2020 Oct; 99:291-297.
Score: 0.097
-
Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
Score: 0.095
-
Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility. PLoS One. 2016; 11(3):e0149094.
Score: 0.072
-
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Perm J. 2014; 18(1):9-13.
Score: 0.062
-
Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013 May 07; 80(19):1734-9.
Score: 0.059
-
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. Mult Scler. 2023 05; 29(6):731-740.
Score: 0.029
-
The intensity of anticoagulant dosing in hospitalized patients with COVID-19: An observational, comparative effectiveness study. J Hosp Med. 2023 01; 18(1):43-54.
Score: 0.028
-
Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 2019 03 05; 92(10):e1016-e1028.
Score: 0.022
-
Association between maternal inflammatory bowel disease and adverse perinatal outcomes. J Perinatol. 2014 Jun; 34(6):435-40.
Score: 0.016